Company Overview
Niagen Bioscience, Inc. operates as a bioscience company focused on the development of healthy aging products, functioning through three distinct segments: consumer products, ingredients, and pharmaceuticals. The company provides finished dietary supplement products containing its proprietary ingredients directly to consumers, leveraging its biotechnology industry classification within the broader healthcare sector. This operational model allows the firm to address market demands for longevity solutions while managing the complexities of both retail and pharmaceutical channels. The company currently holds a market capitalization of $361.96M, supported by an annual revenue of $129.42M and an employee base of 117 individuals. These valuation and revenue figures indicate that Niagen Bioscience, Inc. occupies a mid-cap position within the biotechnology landscape, suggesting a significant operational scale relative to early-stage peers while maintaining a lean organizational structure.
Financial Health
The company reported a revenue of $129.42M over the trailing twelve months, generating a net income of $17.38M and an EBITDA of $15.08M. The gap between the $129.42M revenue and the $17.38M net income reveals a substantial cost structure where approximately 86.6% of top-line revenue is consumed by operating expenses, taxes, and other deductions before reaching the bottom line. Despite the high operating costs, the firm generated free cash flow of $4.88M, which provides a degree of financial flexibility by indicating that the business can fund operations and potential capital expenditures from its own cash generation without relying solely on external financing. Three key margin metrics further define the financial performance: a gross margin of 64.3% indicates strong pricing power and efficient production costs relative to the cost of goods sold; an operating margin of 6.2% highlights the pressure of selling, general, and administrative expenses against gross profits; and a profit margin of 13.4% demonstrates the company's ability to convert revenue into actual earnings after all expenses. Regarding liquidity and leverage, the company holds $64.64M in cash against $2.82M in debt, creating a conservative balance sheet where cash significantly outweighs liabilities. This position is reinforced by a debt-to-equity ratio of 3.68 and a current ratio of 4.86, the latter indicating robust short-term liquidity as the firm possesses nearly five times the current assets required to cover its current liabilities. Finally, the return on equity stands at 28.3% while the return on assets is 10.2%, metrics that collectively reveal management effectiveness in generating returns on shareholder capital relative to the total asset base employed in the business.
Valuation Assessment
Valuation metrics for Niagen Bioscience, Inc. show a trailing P/E ratio of 22.60 compared to a forward P/E of 13.10. The substantial difference between these two figures implies that the market expects a significant decline in earnings or a restructuring of profitability in the coming year, as the forward multiple is less than half the trailing multiple. The price-to-book ratio is 4.72, which indicates a substantial market premium over the company's book value, suggesting investors are pricing in intangible assets or future growth potential rather than just tangible net worth. Alternative valuation measures include a price-to-sales ratio of 2.80 and an EV/EBITDA of 19.95, suggesting the market values the company at nearly three times its sales despite the high valuation multiples. The stock has traded between a 52-week low of $4.39 and a 52-week high of $14.69, with the current trading price situated within this established range but reflecting the high volatility associated with the biotechnology sector. The beta value of 2.23 signifies that the stock price is more than twice as volatile as the broader market, meaning price swings will be amplified during periods of general market movement.
Growth & Income
The company recorded a revenue growth rate of 16.2% year-over-year, while earnings growth stood at -41.6% for the same period. This divergence implies that earnings are growing significantly slower than revenue, or in this case, are contracting despite top-line expansion, which often points to one-time charges, restructuring costs, or a temporary compression in profit margins that does not yet reflect in the bottom line. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company reinvests all of its earnings back into growth initiatives, research, and development rather than distributing cash to shareholders. This strategy prioritizes capital allocation toward expanding the proprietary ingredient portfolio and scaling the consumer and pharmaceutical segments to capture future market share. The overall growth and income profile is characterized by strong top-line expansion and high returns on equity, coupled with a complete absence of current dividend income, positioning the asset as a pure growth play dependent on future profitability improvements.